We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa

VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa

VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa

VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

VistaGen Therapeutics, Inc. has announced that Sanwa Kagaku Kenkyusho Co. Ltd. (Sanwa), an international pharmaceutical company headquartered in Nagoya, Japan, has, pursuant to the terms of the parties’ joint research and development agreement, selected to license three customized ES Cell-based beta-islet differentiation assay systems developed under the agreement. Financial terms were not disclosed.

Sanwa will use these customized ES Cell assays to identify and screen new diabetes drug candidates.

The assay systems were developed to expand the capabilities of VistaGen’s ES Cell technologies to discover novel biologic products to treat diabetes and to accelerate Sanwa’s internal discovery and screening programs for new small molecule drug candidates for Type 1 and Type 2 diabetes.

During the discovery phase of the collaboration, VistaGen and Sanwa leveraged VistaGen’s industry-leading ES Cell technologies and bioinformatics databases to identify biological molecules that can be used to expand beta-islet cell differentiation and/or insulin production.

Several discoveries resulting from these studies are now under evaluation as potential candidates for joint drug development programs. Other than the assay systems licensed by Sanwa, VistaGen has the right to participate equally with Sanwa on any drug development programs involving joint discoveries derived from VistaGen’s technology in the field of diabetes.

Dr. Ralph Snodgrass, VistaGen’s President and CEO, said, “We are pioneering an exciting new era where innovative stem cell technologies give us new tools and approaches to dramatically improve R&D productivity and accelerate the discovery and development of safe and effective new drugs in ways that we never could before.”

He explained that this license of three customized assay systems by Sanwa reflects the pharmaceutical industry’s need for clinically relevant, high quality, differentiated cells suitable for large-scale drug discovery screening.

Working with VistaGen, Sanwa researchers used VistaGen’s proprietary FRED™ knowledgebase system and bioinformatics software tools to analyze the growth and differentiation of stem cell-derived beta-islet cells. The goal was to identify novel genes and growth factors associated with the differentiation and expansion of beta-islets and the regulation of insulin production as potential therapeutic biological molecules or as drug targets.